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We have indentificd a GT-to-fT transversion at the splice donor site of intron 8 in the glycosylasparaginase gene from an African American aspar- 
tylglucosaminuria (AGU) patient. This mutation causes abnormal splicing of glycosylasparaginasc prc-mRNA by joining exon 7 to 9 and excluding 
134 bp exon 8. The erect of the mutation is compounded by a frame shift that occurs after the deletion site resulting in premature translational 
termination. The truncated AGU protein was neither catalytically active nor processed into mature c( and fi subunits. Both this and a previously 
characterized Finnish AGU mutation appear to affect folding of the single-chain precursor of glycosylasparaginase and thereby prevent transport 
of the enzyme to lysosomes. 
Aspartylglucosaminuria: Glycosylasparaginase; Splicing defect 
1, INTRODUCTION 
Aspartylglucosaminuria (AGU) is an inherited dis- 
order of glycoprotein catabolism caused by a deficiency 
of the amidaseglycosylasparaginase (E.C. 3.5.1.X) [I]. 
The disease was first reported by Jenner and Pollitt in 
1968 when they discovered large amounts of GlcNAc- 
Asn in the urine of two mentally retarded British sibl- 
ings [2]. AGU is the third most prominent lysosomal 
storage disease with over 200 documented cases [5], 
however the majority of these are people of Finnish des- 
cent suggesting a founder effect. 
Our laboratory recently isolated a cDNA encoding 
the entire protein coding sequence of human placenta 
glycosylasparaginase [3]. Subsequent to our report, 
Ikonen et al. [4] published a composite cDNA sequence 
of human liver glycosylasparaginase that showed com- 
plete sequence identity with our human placenta cDNA. 
In this latter study two missense point mutations were 
identified in 20 Finnish AGU patiets which were pro- 
posed to be responsible for causing glycosylasparagin- 
ase deficiency. These ‘Finnish type’ mutations were in- 
dependently confirmed by Mononen et al. [5] and 
ourselves (61. We also determined that only one of the 
two resultinp amino ..;id substitutions, Cys’63+Ser, 
abolishes glycosylasparaginase acitivity [6]. In addition, 
this mutation prevents post-translational cleavage of 
the precursor glycosylasparaginasc protein into Q and /3 
subunits that constitute the mature cnzymc [6]. The 
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multiple effects of this Cys’63+Ser Finnish mutation 
strongly suggest that post-transIational cleavage of the 
glycosylasparaginase protein is required for enzymatic 
activity. 
In 1983 Hreidarssson et al. [7] diagnosed AGU in a 
12-year-oId black male. In this report we have charac- 
terized the mutation responsible for AGU in this 
African American patient (Patient TC79-842). The 
genetic cause, exon skipping, is distinct from the Fin- 
nish Cys ‘“‘+Ser mutation, and it is likely that a diversi- 
ty of glycosylasparaginase mutations occur in humans. 
The gene sequence for this lysosomal amidase is 
reported in an accompanying paper [S], and this infor- 
mation will allow the various forms of AGU to be 
characterized at the molecular level. 
2. METHODS AND MATERIALS 
2. I. PCR amptifica/iorr of ~lre g~~~cos~~lasparagir~ase seqgrterrce from 
AGU pa/iertf TC?9-842 
A primary fibroblas[ culture from AGU patient TC79-842 was 
generously provided by Dr George H. Thomas [7] (Kennedy Institute, 
Johns Hopkins University, Baltimore. MD, USA). Total RNA and 
gcnomic DNA were purified from cultured cells as described [(il. 
Three sets of oligonucleotidc primers were used to amplify the 
glycosylnsparaginasc cDNA sequence from AGLJ paficnt TC79-842 
161. The primers wcrc designed such that they would gencratc three se- 
qucntially overlapping fragments that together would span the cntirc 
glycosylasparaginnsc protein coding region. Oligonuclcotidc primsrs 
for PCR amplification of gcnomic DNA wcrcsynthcsizcd from intton 
scqucrlcc that flanks cxon 8 [S] which was found 10 bc dclctcd in pa- 
licnl TC79-842: 
ycnsc-strand primer, 5’ GAAGTAACCGACTCTTGT 3’ 
antisc~isc-slralld primer, S ’ G’l’C’fTGAGATCATCAA’TG 3’ 
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Fig. 1. PCR amplification of the carboxyl-terminal portion of 
glycosylasparaginasc from AGU patient TC79-842. PCR products 
using primers previously described [6] were resolved on a 2.0% 
agarose gel and stained with ethidium bromide (left). The gel was 
Southern blotted on to a nylon membrane and probed with “P- 
labeled cDNA clone HPAsn.6 (right). 
Reaction conditions and thermal cycling parameters for both cDNA 
and genomic DNA PCR amplifications were as described previously 
[G]. PCR fragments were sequenced directly [9] or subsequent to Ml3 
mpl8/19 cloning. DNA sequencing was done from both strands. 
2.2. Expression in COS-I cells 
The glycosylasparaginase cDNA sequence from AGU patient 
TC79-842 (AGU “““s) was subcloned into the expression vector 
pSVL to create the recombinant vector pSVL/AGUAeXon8. Transfec- 
tion of COS-I cells was by the DEAE-dextran method using recombi- 
nant or native pSVL at 5 bg/lOO mm culture dish [IO]. Glycosyl- 
asparaginasc enzyme assays and Western blot analyses were perform- 
ed on transfected cell lysates 48 h post-transfection as described [6]. 
2.3. ImmunojIiorescen~ cell staining 
COS-1 cells were grown in 35-mm culture dishes containing a sterile 
coverslip and transfected by the DEAE-dextran method with I 
p&plate of either pSVL/HPAsn.6 (contains normal human placenta 
cDNA sequence HPAsn.6 [6]), pSVL/AGUJ”” (contains the Finnish 
AGU glycosylasparaginase cDNA sequence [6]), pSVL/AGU”c’o”s, 
or pSVL/RLCBI (contais cDNA sequence RLCBl that encodes rat 
liver di-N-acetylchitobiase (unpublished)). At 48 h post-transfection 
cells were fixed in 3% paraformaldehyde/PBS, incubated with theap- 
propriate rabbit primary antibody, and stained with a secondary goat 
anti-rabbit FITC-conjugated antibody as described [ll]. 
3. RESULTS AND DISCUSSION 
3.1. Identification of the mutation responsible for 
glycosylasparaginuse deficiency in American A G U 
patient TC79-842. 
Agarose gel electrophoresis of PCR products from 
AGU patient TC79-842 cDNA revealed the oligo- 
nucleotide primers that bracket the carboxyl-terminal 
portion of glycosylasparaginase (bp 660-1065) [3] 
amplified a fragment approx. 130 bp shorter in length 
than the expected 404 bp (Fig. 1). In addition to this 
primary product, a minor fragment of approx. 400 bp 
was also visible. Southern blot analysis showed both se- 
quences were homologous to glycosylasparaginase (Fig. 
I). 
A large deletion of 134 bp spanning positions 
807-940 of the protein-coding region of the glyco- 
sylasparaginase gene was confirmed by sequencing the 
270 bp PCR product from patient TC79-842 (Fig. 2). 
Since the deletion does not maintain the open reading 
frame, premature translational termination would 
cause further loss of protein coding sequence. The col- 
lective effects of the 134 bp deletion would result in a 
truncated protein predicted to have an unglycosylated 
mass of 26.4 kDa after removal of the signal peptide 
compared to 34.6 kDa for the normal glycosylaspara- 
ginase sequence [3]. Alignment of the mutant cDNA se- 
quence from patient TC79-842 with the intron-exon 
structure of the glycosylasparaginase gene determined 
by Park et al. [8] in our laboratory revealed the deleted 
134 bp correspond exactly to the sequence encoded by 
exon 8 (Fig. 2). 
To determine the genetic event that resulted in the 
loss of exon 8, oligonucleotide primers were designed 
from flanking intron sequence and used in PCR 
amplification of genomic DNA. Both TC79-842 and 
controls yielded a fragment of approx 430 bp il. agree- 
TC79-842 
265 R F L P R C C L Q *** 
793 CX~;TTCCTGCCAAGGTGCTGCTTGCAATAAACTT... 
t ! 
HPAsn.6 
793 CGCTTCCTGCCAAdCTACCAAGCTGTAGAATAC..96 bp..AATGTGACTGGAAGTTACGGTGCTGCTTGCAATMCTT... 
265 R F L P S Y Q A V E Y ..32 aa.. N V T G S Y G A A C N K L... 
XHGA.121 
. . . tctgtttcaatcagCTACCAAGCTGTAGAATAC.. 96 bp..AATGTGACTGGAAGTTACGgtaagttgtgtttggatttt... 
Pig. 2, Partial alignment of the glycosylasparaginnsc cDNA scqucncc from AGU patient TC79-842 and hu~nan placenta C~OIIC liPAst1.6 13). A 
134.bp scqucncc from HPAsn.6 shown brackctcd bctwccn arrows is dclc~cd from tltcglycosylaspnri~gillilscscquctlce PCR amplified from TC79-842 
RNA ins indicated. A termination siynal TAA indicntcd in bold print and by asterisks was brought in-frame as a result of the 134.bp dclction. EXOII 
8 nnd flnnking intron scqucncc from human placenta clone XHGA.121 [8] is shown below the cDNA scqrrcncc of clone HPAsn.6. Intron sequcncc 
is 8ivcn in lower-cast Icttcring. 
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Fig. 3. Identification of a point mutation in the genomic PCR product from AGU patient TC79-842. The sequence on the left is from genomic 
clone XHGA.121 [S] and the sequence on the right was PCR amplified from TC79-842 genomic DNA. Dideoxynucleotide termination reactions 
appear on the gel in the order G. A, T, C. The DNA sequence is read 5’ to 3’ from bottom to top. The G -+T point mutation discovered at the 
5’ donor splice site of intron 8 is boxed. Arrows point to the exact location of the point mutation. 
ment with the predicted 428 bp. Sequence analysis of 
the product from TC79-842 indicated that deletion of 
exon 8 is likely the result of a splicing defect caused by 
a G+T transversion (Fig. 3). This point mutation 
destroys the GT consensus dinucleotide at the 5 ’ donor 
splice site of intron 8. Northern blotting revealed the 
two glycosylasparaginase m ssages that normally result 
from utilization of different polyadenylation signals 
[6,8] are approx. 150 bp shorter in patient TC79-842 
relative to controls (not shown). Interestingly the G-+T 
point mutation may not completely eliminate splicing at 
the exon I/intron 8 border as evidenced by the minor 
400 bp cDNA PCR product seen in Fig. 1. We have not 
determined whether the mutant donor splice site or a 
nearby cryptic one is being utilized, The deletion of an 
entire exon due to a mutation similar to that presented 
here has been described previously [ 12,131. Among 
lysosomal storage diseases a patient with late infantile 
Tay-Sachs had a G-+A mutation at the last nucleotide 
of exon 5 that produced N-acetyl /3-D-hexosaminidase CY 
mRNA in which exon 5 was skipped [14], This patient 
also produced approx. 3% normally spliced message, 
Another prevalent infantile form of Tay-Sachs has a 
mutation at a consensus plice site position equivalent 
to that seen in AGU patient TC79-842 that is caused by 
a GT-$T transversion at the 5’ donor splice site of in- 
tron 12 [15,16]. The defective nature of mRNA in this 
particular Tay-Sachs group is not a skipped exon as 
observed here, but instead is a set of abnormally spliced 
and unstable messages that can include illtron 12 [17], 
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Fig. 4. Direct scqucncing of gcnomic PCR product from AGU patient 
TC79-842, The 428 bp gcnomic PCR product for exon 8 was gel 
purified and scqucnccd directly using the scnsc or anti-sense strand 
primers dcscribcd in section 2. The scqucncc that is shown used the 
anti-sense strand primer. Rcnctions appear on rhe gel in the order G, 
A, T, C. The scqucncc is read 5’ to 3’ from top to bottom. The G-+f 
point mutation is boxed and indicated with an arrow. 
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Direct sequencing of the genomic PCR fragment 
from patient TC79-842 revealed the G-+T point muta- 
tion was present in the entire population of amplified 
sequences (Fig. 4). This strongly suggests that patient 
TC79-842 is homozygous for the 5 ’ donor splice site 
ACU mutation. The possibility of compound hetero- 
zygosity involving a gene rearrangement not detected 
with the PCR primers used in this study is not likely 
based on Southern blotting experiments of genomic 
DNA from patient TC79-842 (not shown). 
3.2. Expression of the AGU sequence from TC79-842 
The mutant glycosylasparaginase cDNA sequence 
from TC79-842 (AGU ‘exon8) was expressed in COS-1 
cells to determine its catalytic potential. Lysates from 
CC?!!F transfected with the normai giycosyiasparaginase 
cDNA HPAsn.6 expressed 20-fold greater levels of 
Asn-GlcNAc cleaving activity compared to cells 
transfected with the pSVL vector alone (Fig. 5). This in- 
crease in activity was concomitant with the detection of 
the processed 4 subunit on a Western blot (Fig. 5). A 
minor amount of the 41 kDa precursor glycosylas- 
paraginase polypeptide was also evident due to the high 
levels of expression [6]. Cells transfected with the mu- 
tant AGU’cXong sequence did not show an increase in 
glycosylasparaginase activity or the processed CY subunit 
(Fig. 5). However, an immunoreactive 30 kDa polypep- 
-24kDa 
Fig. 5. COS-I ccl1 cxprcssio: of tratlsfcctcd glycosylasparaginnsc 
scquencc from cDNAs HPAsn.6 and American AGU patient 
TC79-842. Lysates from cells transfcctcd with pSVL, pSVL/ 
HPAsn.6 or pSVL/AGU’Cx”“” wcrc rcsolvcd on ;I IS% SDS- 
polyacrylatnidc gel and clcctrophorctically trnnsfcrred to nn 
lmmobilon mcmbranc (Milliporc). Specific a subunit nntibodics wcrc 
used IO dctcct the CI subunit and unproccsscd glycosyluspurngilI;isc. 
Aliquots of the same lyaatcs used for Wcstcrn blotting wcrc also 
tlasaycd for glyCoaylasp~rilgillo~c ilctivity. 
tide that corresponds to the predicted size of the trun- 
cat,ed AGU*exon8 protein was detected. This peptide was 
also weakly antigenic towards fl subunit-specific an- 
tibody (not shown). These data show that the aberrant 
glycosylasparaginase protein is made by patient 
TC79-842, but it is not cleaved post-translationally or 
active. 
3.3. Localization of the mutant AGU pt-otein 
In a previous study we proposed that the Cys’“3+Ser 
mutation common to three Finnish AGU patients 
resulted in the loss of a disulfide bridge that conse- 
quently had a pronounced effect on conformational 
folding of the precursor glycosylasparaginase polypep- 
tide [6]. We further suggested that this inhibited post- 
translational processing to the CY and 6 subunits by cne 
of two mechanisms. Either the incorrectly folded pro- 
tein was trapped in the ER, thus preventing transport to 
the lysosome where the post-translational clippage 
event is thought to occur, or the polypeptide was suc- 
cessfully transported, but was not in the proper confor- 
mation for its cleavage into subunits. This same 
hypothesis can be applied to the mutant glycosylaspara- 
ginase protein from the American AGU patient 
TC79-842, since it was also found not to be processed to 
the (~10 subunit structure. Such a large loss of protein 
coding seqtlence caused by the 134 bp deletion could 
have a significant effect on the folding of the precursor 
polypeptide. 
Immunofluorescent cell staining of transfected 
COS-1 cells was performed to examine cellular localiza- 
tion of both the Finnish and American AGU proteins. 
To first establish the lysosomal staining pattern, COS-1 
cells expressing the rat liver lysosomal exoglycosidase 
di-N-acetylchitobiase [ 181 were stained and found to ex- 
hibit a punctate distribution of fluorescence typical for 
lysosomal labeling [19-211 (Fig. 6a). Cells expressing 
the normal glycosylasparaginase cDNA HPAsn.6 [6] 
also produced the same punctate labeling pattern (Fig. 
6b). Examination of cells expressing either the AGUAFi” 
or AGUAcXon8 sequences revealed a different pattern. In 
both instances the fluorescent label was more evenly 
dispersed extending from the nucleus into the 
cytoplasm (Fig. 6c,d). This same diffuse type of label- 
ing has been shown to occur for a mutant form of CY-D- 
glucosidase that is not transported to the lysosome, but 
instead is found localized in the ER and Golgi [21]. 
The results presented here strongly suggest that muta- 
tions in both Finnish AGU and this new American form 
prevent the aberrant proteins from successfully entering 
the lysosomes due to their entrapment in the ER or 
other early compartments. In addition to the enzyme 
being incorrectly localized, loss of lysosomal targeting 
would have the indirect effect of preventing post- 
translational processing of the precursor polypcptide to 
cy and 0 subunits, a step WC propose to bc necessary for 
glycosylasptlraginasc to bccomc active [6], 
176 
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Fig. 6. Immunofluorescent detection by light microscopy of normal and mutant lysosomal glycosidases in transfected COS-1 cells. Immune 
complexes were visualized with goal anti-rabbit-fluorescein. (a) pSVL/RLCBI (di-N-acetylchitobiase)~transfected cell; (b) pSVL/HPAsn.6 
(normal glycosylasparaginase [3])-tranrfected cell; (c) pSVL/AGUJ”” (Finnish mulam glycosylasparaginasc [Cl)-transfected cell; (d) 
pSVL/AGUJC”o”R (patient TC79-842 mutant glycosylasparaginase)-transfected cell. 
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